-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The 11th specialty API this year! Shijiazhuang Sihua Pharmaceutical Group’s etomidate API has been approved.
Category:
发布时间：2024-06-21
【概要描述】
On June 21, the etomidate API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms. This marks the 11th specialty API that the group has received approval for this year.
On June 21, the etomidate API developed by Hebei Guolong Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved by the National Medical Products Administration and registered as an API for use in marketed dosage forms. This marks the 11th specialty API that the group has received approval for so far this year.
According to available information, etomidate is an anesthetic used for induction of general anesthesia and also for short-duration surgical anesthesia and as an adjunct to anesthesia. In September 2023, the National Medical Products Administration issued an announcement adding etomidate—except for etomidate-containing pharmaceutical preparations approved for marketing in China—to the Catalogue of Psychotropic Substances of the Second Category, effective October 1, 2023.
In recent years, Shijiazhuang Sihua Pharmaceutical Group has focused on the needs of the high-end, complex formulation industry chain, actively promoting integrated “API–formulation” development, intensifying the R&D of new products, and continuously enhancing the diversification and reliability of supply across the industry and supply chains, thereby providing robust support for expanding sustainable growth opportunities. Currently, the group boasts 57 bulk and specialty API varieties, with an increasingly diversified product portfolio that is powerfully accelerating the transition to integrated “API–formulation” development.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091